Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mucofert is a small molecule nutraceutical supplement developed and marketed by Adorshea Bioceutics, primarily indicated for the management of female infertility by improving cervical mucus quality. The product's active ingredient is N-acetylcysteine (NAC), which functions as a mucolytic agent. NAC works by cleaving the disulfide bonds in mucoproteins, thereby reducing the viscosity of cervical mucus and facilitating easier sperm penetration and migration. Additionally, NAC acts as a precursor to glutathione, providing antioxidant support that can enhance ovulatory function and improve pregnancy rates, particularly in women with Polycystic Ovary Syndrome (PCOS) or unexplained infertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mucofert.